74 related articles for article (PubMed ID: 23573980)
1. A truncated plasmid-encoded HIV-1 reverse transcriptase displays strong immunogenicity.
Hallengärd D; Wahren B; Bråve A
Viral Immunol; 2013 Apr; 26(2):163-6. PubMed ID: 23573980
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 reverse transcriptase artificially targeted for proteasomal degradation induces a mixed Th1/Th2-type immune response.
Starodubova ES; Boberg A; Litvina M; Morozov A; Petrakova NV; Timofeev A; Latyshev O; Tunitskaya V; Wahren B; Isaguliants MG; Karpov VL
Vaccine; 2008 Sep; 26(40):5170-6. PubMed ID: 18468738
[TBL] [Abstract][Full Text] [Related]
3. DNA-encoding enzymatically active HIV-1 reverse transcriptase, but not the inactive mutant, confers resistance to experimental HIV-1 challenge.
Isaguliants MG; Petrakova NN; Zuber B; Pokrovskaya K; Gizatullin R; Kostyuk DA; Kjerrström A; Winberg G; Kochetkov SN; Hinkula J; Wahren B
Intervirology; 2000; 43(4-6):288-93. PubMed ID: 11251384
[TBL] [Abstract][Full Text] [Related]
4. Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity.
Hallengärd D; Haller BK; Petersson S; Boberg A; Maltais AK; Isaguliants M; Wahren B; Bråve A
Vaccine; 2011 Jan; 29(4):839-48. PubMed ID: 21109032
[TBL] [Abstract][Full Text] [Related]
5. Potent cross-reactive immune response against the wild-type and drug-resistant forms of HIV reverse transcriptase after the chimeric gene immunization.
Starodubova E; Boberg A; Ivanov A; Latyshev O; Petrakova N; Kuzmenko Y; Litvina M; Chernousov A; Kochetkov S; Karpov V; Wahren B; Isaguliants MG
Vaccine; 2010 Feb; 28(8):1975-86. PubMed ID: 20188253
[TBL] [Abstract][Full Text] [Related]
6. Reverse transcriptase-based DNA vaccines against drug-resistant HIV-1 tested in a mouse model.
Isaguliants MG; Zuber B; Boberg A; Sjöstrand D; Belikov SV; Rollman E; Zuber AK; Rechinsky VO; Rytting AS; Källander CF; Hinkula J; Kochetkov SN; Liu M; Wahren B
Vaccine; 2004 Apr; 22(13-14):1810-9. PubMed ID: 15068865
[TBL] [Abstract][Full Text] [Related]
7. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity testing of a novel engineered HIV-1 envelope gp140 DNA vaccine construct.
Kumar S; Yan J; Muthumani K; Ramanathan MP; Yoon H; Pavlakis GN; Felber BK; Sidhu M; Boyer JD; Weiner DB
DNA Cell Biol; 2006 Jul; 25(7):383-92. PubMed ID: 16848679
[TBL] [Abstract][Full Text] [Related]
9. Oxidative stress induced by HIV-1 reverse transcriptase modulates the enzyme's performance in gene immunization.
Isaguliants M; Smirnova O; Ivanov AV; Kilpelainen A; Kuzmenko Y; Petkov S; Latanova A; Krotova O; Engström G; Karpov V; Kochetkov S; Wahren B; Starodubova E
Hum Vaccin Immunother; 2013 Oct; 9(10):2111-9. PubMed ID: 23881028
[TBL] [Abstract][Full Text] [Related]
10. Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice.
Okazaki T; Terabe M; Catanzaro AT; Pendleton CD; Yarchoan R; Berzofsky JA
J Virol; 2006 Nov; 80(21):10645-51. PubMed ID: 16920824
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
12. Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.
Latanova AA; Petkov S; Kilpelainen A; Jansons J; Latyshev OE; Kuzmenko YV; Hinkula J; Abakumov MA; Valuev-Elliston VT; Gomelsky M; Karpov VL; Chiodi F; Wahren B; Logunov DY; Starodubova ES; Isaguliants MG
Sci Rep; 2018 May; 8(1):8078. PubMed ID: 29799015
[TBL] [Abstract][Full Text] [Related]
13. Fusion to Flaviviral Leader Peptide Targets HIV-1 Reverse Transcriptase for Secretion and Reduces Its Enzymatic Activity and Ability to Induce Oxidative Stress but Has No Major Effects on Its Immunogenic Performance in DNA-Immunized Mice.
Latanova A; Petkov S; Kuzmenko Y; Kilpeläinen A; Ivanov A; Smirnova O; Krotova O; Korolev S; Hinkula J; Karpov V; Isaguliants M; Starodubova E
J Immunol Res; 2017; 2017():7407136. PubMed ID: 28717654
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
Jiang W; Ren L; Jin N
J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
[TBL] [Abstract][Full Text] [Related]
15. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
[TBL] [Abstract][Full Text] [Related]
16. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
17. Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C.
Burgers WA; Shephard E; Monroe JE; Greenhalgh T; Binder A; Hurter E; Van Harmelen JH; Williamson C; Williamson AL
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):195-206. PubMed ID: 18240957
[TBL] [Abstract][Full Text] [Related]
18. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
[TBL] [Abstract][Full Text] [Related]
19. Introducing a frameshift mutation to the POL sequence of HIV-1 provirus and evaluation of the immunogenic characteristics of the mutated virions (RINNL4-3).
Zabihollahi R; Sadat SM; Vahabpour R; Salehi M; Azadmanesh K; Siadat SD; Saraji AR; Pouriavali MH; Momen SB; Aghasadeghi MR
Mol Biol (Mosk); 2012; 46(3):519-24. PubMed ID: 22888641
[TBL] [Abstract][Full Text] [Related]
20. Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine.
Yan J; Yoon H; Kumar S; Ramanathan MP; Corbitt N; Kutzler M; Dai A; Boyer JD; Weiner DB
Mol Ther; 2007 Feb; 15(2):411-21. PubMed ID: 17235321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
